AHR-5850: a potent anti-inflammatory compound.
AHR-5850 is a non-steroidal anti-inflammatory compound possessing antipyretic and analgesic properties. AHR-5850 was 16.4 and 22.8 times more potent than phenylbutazone in suppressing acute (Evans blue-carrageenan pleural effusion) and chronic (adjuvant-induced arthritis) inflammation, respectively. The analgesic activity of AHR 5850 was 43 times that of acetylsalicylic acid in the Randall-Selitto assay, and 156 and 56.3 times more potent than phenylbutazone in the acetylcholine-induced abdominal constriction in mice and in the bradykinin-induced nociceptive response in dogs, respectively. Single-dose studies showed that AHR-5850 produced less gastric irritation than acetylsalicylic acid when applied topically to the exposed gastric mucosa of cats or when administered orally to rats and dogs. Upon subchronic oral administration to rats, the therapeutic ratio of AHR-5850 was twice that of phenylbutazone. This was based on the ratio of its potency relative to phenylbutazone in producing intestinal lesions to its anti-inflammatory potency relative to phenylbutazone in the adjuvant-induced arthritis.
D000208:Acute Disease; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001577:Benzophenones / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D002415:Cats; D002908:Chronic Disease; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D004487:Edema / Q000188:drug therapy; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects; D008297:Male; D051379:Mice; D010648:Phenylacetates / Q000627:therapeutic use*; D051381:Rats; D013045:Species Specificity; D014044:Tolbutamide / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D001577:Benzophenones; D001786:Blood Glucose; D010648:Phenylacetates; C014285:amfenac; D014044:Tolbutamide